Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 4/20 | 0.41 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.36 |
| ▸ | CNR1 | P21554 | 11/20 | 0.36 |
| ▸ | CNR2 | P34972 | 5/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18546998 | 0.91 | FPR2 (0.41) | FPR2CNR1CNR2 | |
| Trifluoroacetic Acid SCHEMBL18547759 | 0.79 | IDO1 (0.40) | CNR1CNR2 | |
| Trifluoroacetic Acid SCHEMBL18547107 | 0.79 | CNR1 (0.44) | CNR1CNR2 | |
| Trifluoroacetic Acid SCHEMBL18547404 | 0.76 | CNR1 (0.43) | CNR1CNR2 | |
| SCHEMBL18562563 | 0.76 | CNR1 (0.54) | CNR1CNR2 | |
| Hydrochloric Acid SCHEMBL18546900 | 0.75 | CNR1 (0.54) | CNR1CNR2 | |
| SCHEMBL18547495 | 0.75 | CNR1 (0.57) | FPR2CNR1CNR2 | |
| SCHEMBL18547384 | 0.74 | CYP11B1 (0.38) | CNR1CNR2 | |
| Trifluoroacetic Acid SCHEMBL18547121 | 0.74 | RECQL (0.43) | TBXA2RCNR1CNR2PPARG | |
| Trifluoroacetic Acid SCHEMBL18547560 | 0.73 | CNR1 (0.41) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190031618-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2019-01-31 | — | — | US | disclosed |
| US-10118900-B2 | Benzimidazole derivatives useful as CB-1 inverse agonists | JANSSEN PHARMACEUTICA NV (BE) | 2018-11-06 | — | — | US | disclosed |
| US-20170057929-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2017-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190031618-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | CNR1, GPR119, CNR2 | FPR2 1896/4885TBXA2R 57/4885CNR1 1/4885 |
| US-20170057929-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | CNR1, GPR119, CNR2 | FPR2 1924/4885TBXA2R 58/4885CNR1 1/4885 |
| US-10118900-B2 | Benzimidazole derivatives useful as CB-1 inverse agonists | CNR1, GPR119, CNR2 | FPR2 1924/4885TBXA2R 58/4885CNR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.